IDH1 inhibitor shows promising early results.

Authors
Category Primary study
JournalCancer discovery
Year 2015
The experimental drug AG-120, which inhibits mutant IDH1, showed promising results in a phase I trial in patients with relapsed or refractory acute myeloid leukemia.
Epistemonikos ID: 7c3da80c95886517a1e034b5143b4126aa2937b0
First added on: Jan 21, 2022